Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02843633
Other study ID # 16US01
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date February 14, 2017
Est. completion date March 2021

Study information

Verified date February 2021
Source Biosensors Europe SA
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to confirm non-inferiority of the BioFreedom™ Drug Coated Stent to the Gazelle™ Bare Metal Stent arm of the Leaders Free study (NCT01623180) in high bleeding risk patients.


Description:

In this study all patients will receive the BioFreedom™ Drug Coated Stent and one month of Dual Anti Platelet Therapy


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 1203
Est. completion date March 2021
Est. primary completion date October 11, 2018
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: Any indication for percutaneous coronary intervention with stent placement (PCI-S) in patients deemed at high risk for bleeding and candidates for 1 month dual anti-platelet therapy (DAPT). This includes candidates with stable angina, silent ischemia, acute coronary syndrome (STEMI and non-STEMI), non-native lesions and in-stent restenosis. Patients must provide written informed consent. Reasons of unsuitability for > 1 month dual antiplatelet treatment must include one or more of the following: 1. Adjunctive oral anticoagulation treatment planned to continue after PCI 2. Age = 75 years old 3. Baseline Hgb <11 g/dl (or anemia requiring transfusion during the 4 weeks prior to the index procedure) 4. Any prior intracerebral bleed 5. Any stroke in the last 12 months 6. Hospital admission for bleeding during the prior 12 months 7. Non skin cancer diagnosed or treated < 3 years, with a perceived increased risk for bleeding 8. Planned daily Nonsteroidal anti-inflammatory drugs (NSAID) (other than aspirin) or steroids for >30 days after PCI 9. Planned surgery that would require interruption of DAPT (within next 6 months) 10. Renal failure defined as: Creatinine clearance <40 ml/min 11. Thrombocytopenia (PLT <100,000/mm3) 12. Severe chronic liver disease defined as: patients who have developed any of the following: variceal hemorrhage, ascites, hepatic encephalopathy or jaundice 13. Expected non-compliance to prolonged DAPT for other medical reasons Exclusion Criteria: 1. Pregnant and breastfeeding women 2. Patients expected not to comply with 1 month DAPT 3. Patients requiring a planned staged PCI procedure more than one week after the index procedure 4. Procedure planned to require non-study stents, or stand-alone plain old balloon angioplasty (POBA) or stand-alone atherectomy 5. Active bleeding at the time of inclusion 6. Reference vessel diameter <2.25 - >4.0mm 7. Cardiogenic shock 8. Compliance with long-term single anti-platelet therapy unlikely 9. A known hypersensitivity or contraindication to aspirin, clopidogrel (or prasugrel, or ticagrelor if applicable), stainless steel, zinc, Biolimus A9™ or a sensitivity to contrast media, which cannot be adequately pre-medicated 10. PCI during the previous 12 months for a lesion other than the target lesion of the index procedure 11. Participation in another clinical trial (12 months after index procedure) 12. Patients with a life expectancy of < 12 months 13. Patients under judicial protection, tutorship or curatorship (for France only)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
BioFreedom™ Drug Coated Coronary Stent System
a non-surgical procedure that uses a catheter to place a stent to open up coronary arteries that have been narrowed by atherosclerosis
Drug:
Antiplatelet Drug
Dual antiplatelet therapy for one month followed by single antiplatelet therapy indefinitely. Aspirin and clopidogrel (or other P2Y12 inhibitor) will be used and dosing is according to standard institutional practice

Locations

Country Name City State
Canada Mazankowski Alberta Heart Institute Edmonton Alberta
Canada Hamilton Health Sciences Hamilton Ontario
Canada Centre Hospitalier de l'université de Montréal Montréal Quebec
Canada Hôpital Maisonneuve-Rosemont Montréal Quebec
Canada Montreal Heart Institute Montréal Quebec
Canada Fraser Clinical Trials Inc. New Westminster British Columbia
Canada The University of Ottawa Heart Institute Ottawa Ontario
Canada Institut universitaire de cardiologie et de pneumologie de Québec Québec Quebec
Canada CIUSSS de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke Sherbrooke Quebec
Canada St. Paul's Hospital Vancouver British Columbia
Canada Victoria Heart Institute Foundation Victoria British Columbia
Denmark Rigshospitalet Copenhagen University Hospital Copenhagen
France Clinique Axium Aix-en-Provence
France Service de Cardiologie Interventionnelle - Pôle Santé République Clermont-Ferrand
France Clinique de Fontaine Fontaine-lès-Dijon
France Groupe Hospitalier Mutualiste de Grenoble Grenoble
France Hôpital Privé Jacques Cartier ICPS Massy
France Hôpital Privé Claude Galien Quincy-sous-Sénart
France Clinique Saint Hilaire Rouen
France CHU Toulouse Rangeuil Toulouse
Germany Segeberger Kliniken GmbH Bad Segeberg
Germany Herzzentrum Leipzig GmbH Leipzig
Italy Grande Ospedale Metropolitano Niguarda Milan
Italy Azienda Ospedaliera San Camillo Forlanini Rome
United Kingdom Royal Bournemouth Hospital, Dorset Heart Centre Bournemouth
United Kingdom Craigavon Cardiac Centre Craigavon
United Kingdom Golden Jubilee National Hospital Glasgow
United States AnMed Health Anderson South Carolina
United States McLaren Bay Region Bay City Michigan
United States St. Luke's Idaho Cardiology Associates Boise Idaho
United States University of Buffalo Buffalo New York
United States Lahey Clinic Burlington Massachusetts
United States Novant Health Heart and Vascular Institute Charlotte North Carolina
United States Chattanooga Heart Institute Chattanooga Tennessee
United States Jesse Brown VA Medical Center Chicago Illinois
United States Missouri Cardiovascular Specialists, LLP Columbia Missouri
United States North Georgia Heart Foundation Gainesville Georgia
United States LeBauer Cardiovascular Research Foundation Greensboro North Carolina
United States Penn State - Milton S. Hershey Medical Center Hershey Pennsylvania
United States Tri-Lakes Research Hot Springs Arkansas
United States Houston Methodist Hospital Houston Texas
United States Heart Center Research, LLC Huntsville Alabama
United States St. Vincent Heart Center Indianapolis Indiana
United States University of Florida Jacksonville Jacksonville Florida
United States Saint Luke's Hospital of Kansas City Kansas City Missouri
United States Tennova Healthcare-Turkey Creek Medical Center Knoxville Tennessee
United States Scripps Health La Jolla California
United States University of California San Diego La Jolla California
United States Jewish and St. Mary's Hospital Louisville Kentucky
United States MidMichigan Medical Center Midland Midland Michigan
United States Columbia University Medical Center/New York Presbyterian Hospital New York New York
United States Weill Cornell Medical College-New York Presbyterian New York New York
United States Penn Presbyterian Medical Center Philadelphia Pennsylvania
United States Rhode Island Hospital Providence Rhode Island
United States NC Heart and Vascular Research Raleigh North Carolina
United States Black Hills Cardiovascular Research Rapid City South Dakota
United States Berks Cardiologists, Ltd. Reading Pennsylvania
United States Carilion Clinic Roanoke Virginia
United States William Beaumont Hospital Royal Oak Michigan
United States Santa Barbara Cottage Hospital Santa Barbara California
United States Velella Research Sarasota Florida
United States Tallahassee Research Institute, Inc. Tallahassee Florida
United States Providence Health Center Waco Texas
United States MedStar Washington Hospital Center Washington District of Columbia
United States Pinnacle Health Cardiovascular Institute Wormleysburg Pennsylvania
United States Genesis Healthcare System Zanesville Ohio

Sponsors (1)

Lead Sponsor Collaborator
Biosensors Europe SA

Countries where clinical trial is conducted

United States,  Canada,  Denmark,  France,  Germany,  Italy,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary The composite of cardiac death and myocardial infarction at twelve months 12 months
Primary The incidence of clinically driven target lesion revascularization at twelve months 12 months
Secondary The composite of cardiac death and myocardial infarction 1, 2, and 6 months and 2 and 3 years
Secondary The incidence of clinically driven target lesion revascularization 1, 2, and 6 months and 2 and 3 years
Secondary The composite of cardiac death, myocardial infarction and stent thrombosis 1, 2, and 6 months and 1, 2, and 3 years
Secondary Bleeding per Bleeding Academic Research Consortium (BARC) Criteria 1, 2, and 6 months and 1, 2, and 3 years
Secondary Cardiac Death 1, 2, and 6 months and 1, 2, and 3 years
Secondary Myocardial Infarction 1, 2, and 6 months and 1, 2, and 3 years
Secondary Stent Thrombosis per Academic Research Consortium (ARC) Definition 1, 2, and 6 months and 1, 2, and 3 years
Secondary Urgent target lesion revascularization 1, 2, and 6 months and 1, 2, and 3 years
Secondary Clinically driven target lesion revascularization at time points other than primary endpoint followed for all target lesion revascularizations, up to 3 years
Secondary Clinically driven target vessel revascularization 1, 2, and 6 months and 1, 2, and 3 years
Secondary All cause mortality 1, 2, and 6 months and 1, 2, and 3 years
Secondary Primary endpoints, in patients with at least 1 lesion treated with a trial stent of 3mm or less in nominal diameter 1, 2, and 6 months and 1, 2, and 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06013813 - Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI N/A
Recruiting NCT05412927 - AngelMed Guardian® System PMA Post Approval Study
Completed NCT02750579 - Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes? N/A
Completed NCT04102410 - Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients N/A
Enrolling by invitation NCT03342131 - Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome N/A
Recruiting NCT01218776 - International Survey of Acute Coronary Syndromes in Transitional Countries
Enrolling by invitation NCT04676100 - International CR Registry
Completed NCT03590535 - 5th Generation cTnT in ED ACS
Recruiting NCT05437900 - INSIGHTFUL-FFR Clinical Trial Phase 4
Completed NCT05551429 - Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
Terminated NCT04316481 - IDE-ALERTS Continued Access Study N/A
Active, not recruiting NCT04475380 - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Not yet recruiting NCT04852146 - Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
Active, not recruiting NCT02892903 - In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes? N/A
Completed NCT04077229 - Piloting Text Messages to Promote Positive Affect and Physical Activity N/A
Completed NCT02944123 - Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR) Phase 3
Not yet recruiting NCT02871622 - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM N/A
Active, not recruiting NCT02922140 - The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit N/A
Terminated NCT02620202 - Aiming Towards Evidence Based Interpretation of Cardiac Biomarkers in Patients Presenting With Chest Pain